nasopharyngeal carcinoma
Conditions
Interventions
experimental group :induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy
Sponsors
Affiliated Cancer Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Histologically proven WHO types II-III nasopharyngeal carcinoma; 2) Stage III-IVa(except T3-4N0 and T3N1)(8th AJCC); 3) Expected survival >= 3 months; 4) Male or female aged 65-75 years; 5) Good organ function and no use of blood products and cell growth factors within 2 weeks before treatment; Total bilirubin (TBIL) = 80 mL/min; absolute neutrophil count >= 2.0 x 10^9/L, hemoglobin >= 90 g/L; platelets >= 100 x 10^9/L; 6) ECOG PS 0-1 point; 7) The patient has signed an informed consent form.
Exclusion criteria
Exclusion criteria: 1)History of previous radiotherapy, chemotherapy or surgery (except diagnostic) to primary tumor or nodes; 2)With mental, social, family or geographic factors that will affect the follow-up; 3)Participated in another clinical trials of any research drug; 4)Known to be allergic to potentially used chemotherapy drugs; 5)With sever infection and internal disease; 6)Major organ dysfunction, such as decompensated cardiopulmonary, kidney, liver failure, cannot tolerate surgical treatment; 7)Conditions that may adversely affect treatment compliance: such as psychiatric disorders, central nervous system disorders, chronic diarrhea, ascites and hydrothorax; 8)Long-term use of immunosuppressive agents after organ transplantation; 9)Other malignancy before inclusion, except for non-melanocytoma skin cancer, carcinoma in situ of the cervix unable to tolerate chemotherapy and already cured early stage of prostate cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Quality of life;Safety;Locoregional Relapse-Free Survival;Distant Metastasis-Free Survival; | — |
Countries
China
Contacts
Public ContactWeijun Zhang
Department of Radiotherapy, Affiliated Cancer Hospital of Guangzhou Medical University
Outcome results
None listed